Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 22,400 shares, a drop of 80.4% from the December 15th total of 114,200 shares. Approximately 5.3% of the shares of the company are short sold. Based on an average daily trading volume, of 1,430,000 shares, the days-to-cover ratio is presently 0.0 days.

Avalon GloboCare Price Performance

NASDAQ:ALBT traded down $0.16 during mid-day trading on Monday, hitting $3.29. The company’s stock had a trading volume of 12,786 shares, compared to its average volume of 42,255. The business’s fifty day moving average is $3.32 and its two-hundred day moving average is $4.15. The stock has a market cap of $3.60 million, a price-to-earnings ratio of -0.16 and a beta of 0.19. Avalon GloboCare has a 1 year low of $2.11 and a 1 year high of $21.60.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.